NYSE:MD - MEDNAX Stock Price, Price Target & More

$52.00 -0.78 (-1.48 %)

(As of 04/19/2018 04:00 PM ET)

Previous Close$52.00

Today's Range$51.69 - $52.78

52-Week Range$40.56 - $63.04

Volume505,177 shs

Average Volume868,622 shs

Market Capitalization$4.93 billion

P/E Ratio16.51

Dividend YieldN/A

Beta0.23

About MEDNAX (NYSE:MD)

MEDNAX, Inc. is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company's national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications. As of December 31, 2016, the Company had over 1,390 affiliated physicians providing anesthesia care to patients in connection with surgical and other procedures, as well as pain management. As of December 31, 2016, the Company had 270 affiliated physicians providing maternal-fetal and obstetrical medical care to expectant mothers experiencing complicated pregnancies primarily in areas where its affiliated neonatal physicians practice.

Receive MD News and Ratings via Email

Sign-up to receive the latest news and ratings for MD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Hospitals

Sub-IndustryHealth Care Services

SectorMedical

SymbolNYSE:MD

CUSIP58502B10

Webwww.mednax.com

Phone954-384-0175

Debt

Debt-to-Equity Ratio0.60%

Current Ratio1.18%

Quick Ratio1.18%

Price-To-Earnings

Trailing P/E Ratio16.51

Forward P/E Ratio13.03

P/E Growth1.32

Sales & Book Value

Annual Sales$3.46 billion

Price / Sales1.41

Cash Flow$4.2380 per share

Price / Cash12.27

Book Value$32.74 per share

Price / Book1.59

Profitability

EPS (Most Recent Fiscal Year)$3.15

Net Income$320.37 million

Net Margins9.26%

Return on Equity10.10%

Return on Assets5.23%

Miscellaneous

Employees7,675

Outstanding Shares93,800,000

How to Become a New Pot Stock Millionaire

MEDNAX (NYSE:MD) Frequently Asked Questions

What is MEDNAX's stock symbol?

MEDNAX trades on the New York Stock Exchange (NYSE) under the ticker symbol "MD."

How were MEDNAX's earnings last quarter?

MEDNAX Inc (NYSE:MD) posted its quarterly earnings results on Thursday, February, 8th. The company reported $0.87 EPS for the quarter, beating the consensus estimate of $0.83 by $0.04. The business earned $910.82 million during the quarter, compared to analyst estimates of $884.55 million. MEDNAX had a net margin of 9.26% and a return on equity of 10.10%. The company's quarterly revenue was up 9.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.00 EPS. View MEDNAX's Earnings History.

When is MEDNAX's next earnings date?

MEDNAX is scheduled to release their next quarterly earnings announcement on Wednesday, May, 2nd 2018. View Earnings Estimates for MEDNAX.

What guidance has MEDNAX issued on next quarter's earnings?

MEDNAX updated its first quarter earnings guidance on Thursday, February, 8th. The company provided EPS guidance of $0.84-0.89 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.79.

What price target have analysts set for MD?

13 brokerages have issued 1-year price targets for MEDNAX's stock. Their forecasts range from $47.00 to $62.00. On average, they expect MEDNAX's stock price to reach $55.3333 in the next year. View Analyst Ratings for MEDNAX.

Who are some of MEDNAX's key competitors?

Some companies that are related to MEDNAX include Eurofins Scientific (ERFSF), BioM�rieux (BMXMF), Jazz Pharmaceuticals (JAZZ), WellCare (WCG), BeiGene (BGNE), bluebird bio (BLUE), STERIS (STE), Seattle Genetics (SGEN), Bio-Rad Laboratories (BIO), AveXis (AVXS), SAGE Therapeutics (SAGE), Valeant Pharmaceuticals International (VRX), Alkermes (ALKS), Neurocrine Biosciences (NBIX), West Pharmaceutical Services (WST), ICON (ICLR), Exelixis (EXEL) and Stada Arzneimittel (STDAF).

Who are MEDNAX's key executives?

MEDNAX's management team includes the folowing people:

Cesar L. Alvarez, Chairman of the Board (Age 69)
Joseph M. Calabro, President, Chief Operating Officer (Age 56)
Roger J. Medel M.D., Chief Executive Officer, Director (Age 70)
Vivian Lopez-Blanco, Chief Financial Officer, Treasurer (Age 59)
David A. Clark, President - MEDNAX National Medical Group Division (Age 50)
John C. Pepia, Senior Vice President, Chief Accounting Officer (Age 54)
Dominic J. Andreano, Senior Vice President, General Counsel, Secretary (Age 48)
Manuel Kadre, Lead Independent Director (Age 51)
Karey D. Barker, Independent Director (Age 49)
Waldemar A. Carlo M.D., Independent Director (Age 64)

Has MEDNAX been receiving favorable news coverage?

News stories about MD stock have been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. MEDNAX earned a news sentiment score of 0.17 on Accern's scale. They also gave media headlines about the company an impact score of 46.42 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

How do I buy shares of MEDNAX?

Shares of MD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is MEDNAX's stock price today?

One share of MD stock can currently be purchased for approximately $52.00.

How big of a company is MEDNAX?

MEDNAX has a market capitalization of $4.93 billion and generates $3.46 billion in revenue each year. The company earns $320.37 million in net income (profit) each year or $3.15 on an earnings per share basis. MEDNAX employs 7,675 workers across the globe.

How can I contact MEDNAX?

MEDNAX's mailing address is 1301 CONCORD TERRACE, SUNRISE FL, 33323. The company can be reached via phone at 954-384-0175 or via email at [email protected]

MarketBeat Community Rating for MEDNAX (MD)

Community Ranking:		2.4 out of 5 ( )
Outperform Votes:		323 (Vote Outperform)
Underperform Votes:		355 (Vote Underperform)
Total Votes:		678

MarketBeat's community ratings are surveys of what our community members think about MEDNAX and other stocks. Vote "Outperform" if you believe MD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MD will underperform the S&P 500 over the long term. You may vote once every thirty days.

MEDNAX (NYSE:MD) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

13 Wall Street analysts have issued ratings and price targets for MEDNAX in the last 12 months. Their average twelve-month price target is $55.3333, suggesting that the stock has a possible upside of 6.41%. The high price target for MD is $62.00 and the low price target for MD is $47.00. There are currently 1 sell rating, 9 hold ratings and 3 buy ratings for the stock, resulting in a consensus rating of "Hold."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Hold	Hold	Hold	Hold
Consensus Rating Score:	2.15	2.17	2.17	2.08
Ratings Breakdown:	1 Sell Rating(s) 9 Hold Rating(s) 3 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 8 Hold Rating(s) 3 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 8 Hold Rating(s) 3 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 9 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$55.3333	$55.1818	$53.8182	$55.4444
Price Target Upside:	6.41% upside	3.78% downside	2.45% upside	31.11% upside

MEDNAX (NYSE:MD) Consensus Price Target History

Price Target History for MEDNAX (NYSE:MD)

MEDNAX (NYSE:MD) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
3/27/2018	Credit Suisse Group	Initiated Coverage	Neutral	$57.00	Low
3/15/2018	Jefferies Group	Set Price Target	Hold	$58.00	Low
2/12/2018	BMO Capital Markets	Boost Price Target	Market Perform -> Market Perform	$46.00 -> $58.00	Low
2/12/2018	JPMorgan Chase	Boost Price Target	Neutral -> Neutral	$46.00 -> $55.00	Low
2/9/2018	Mizuho	Reiterated Rating	Neutral -> Neutral	$49.00 -> $53.00	Low
2/9/2018	Robert W. Baird	Boost Price Target	Neutral -> Neutral	$48.00 -> $54.00	Medium
2/8/2018	Stephens	Set Price Target	Buy	$62.00	Medium
1/24/2018	Stifel Nicolaus	Reiterated Rating	Hold	$56.00	Low
12/21/2017	SunTrust Banks	Set Price Target	Hold	$55.00	Medium
12/13/2017	Piper Jaffray	Initiated Coverage	Overweight -> Overweight	$58.00	Low
11/3/2017	Citigroup	Lower Price Target	Neutral	$52.00 -> $47.00	N/A
11/1/2017	KeyCorp	Set Price Target	Buy	$51.00	N/A
5/4/2017	Bank of America	Downgrade	Buy -> Underperform		Low
12/9/2016	Goldman Sachs	Initiated Coverage	Neutral	$66.00	N/A
10/27/2016	Raymond James	Downgrade	Outperform -> Market Perform		N/A
10/27/2016	UBS	Downgrade	Outperform -> Market Perform		N/A

(Data available from 4/19/2016 forward)

MEDNAX (NYSE:MD) Earnings History and Estimates Chart

Earnings by Quarter for MEDNAX (NYSE:MD)

MEDNAX (NYSE:MD) Earnings Estimates

2018 EPS Consensus Estimate: $3.91

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	2	$0.78	$0.80	$0.79
Q2 2018	2	$0.97	$1.02	$1.00
Q3 2018	2	$1.06	$1.06	$1.06
Q4 2018	2	$1.03	$1.09	$1.06

MEDNAX (NYSE MD) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/2/2018		$0.82					N/A
2/8/2018	Q4 2017	$0.8330	$0.87	$884.55 million	$910.82 million	View	N/A
11/1/2017	Q3 2017	$0.87	$0.87	$864.78 million	$868.95 million	View	N/A
7/28/2017	Q2 2017	$0.81	$0.85	$849.49 million	$843.00 million	View	N/A
5/4/2017	Q1 2017	$0.7440	$0.75	$837.01 million	$835.60 million	View	N/A
4/20/2017	Q1 2017	$0.81	$0.70	$839.25 million	$836.00 million	View	N/A
2/7/2017	Q416	$1.06	$1.00	$842.15 million	$831.00 million	View	Listen
10/27/2016	Q316	$1.05	$1.09	$821.18 million	$828.00 million	View	Listen
7/28/2016	Q216	$1.07	$1.03	$775.68 million	$772.00 million	View	Listen
4/28/2016	Q116	$0.86	$0.87	$741.49 million	$752.60 million	View	Listen
2/4/2016	Q415	$1.10	$1.13	$748.02 million	$742.00 million	View	Listen
10/29/2015	Q315	$0.97	$1.10	$730.63 million	$722.30 million	View	Listen
7/30/2015	Q215	$0.88	$0.97	$677.02 million	$676.60 million	View	Listen
4/30/2015	Q115	$0.71	$0.72	$641.24 million	$639.40 million	View	Listen
1/29/2015	Q414	$0.87	$0.89	$637.90 million	$651.00 million	View	Listen
10/30/2014	Q314	$0.85	$0.86	$619.61 million	$627.00 million	View	Listen
7/31/2014	Q214	$0.78	$0.79	$603.00 million	$595.54 million	View	Listen
5/1/2014	Q114	$0.63	$0.63	$574.80 million	$566.00 million	View	Listen
1/30/2014	Q4	$0.75	$0.20	$555.30 million	$567.00 million	View	Listen
10/31/2013	Q313	$1.48	$1.52	$556.63 million	$555.00 million	View	Listen
7/30/2013	Q2 2013	$1.36	$1.37	$533.39 million	$529.18 million	View	Listen
5/2/2013	Q1 2013	$1.09	$1.10	$504.24 million	$502.70 million	View	Listen
1/31/2013	Q4 2012	$1.30	$1.32	$473.70 million	$471.30 million	View	Listen
11/1/2012	Q312	$1.28	$1.32	$470.60 million	$473.10 million	View	N/A
7/31/2012		$1.19	$1.22			View	N/A
5/3/2012		$1.00	$0.98			View	N/A
2/2/2012		$1.19	$1.19			View	N/A
11/1/2011		$1.18	$1.19			View	N/A
8/2/2011		$1.15	$1.15			View	N/A
5/3/2011		$0.91	$0.94			View	N/A
2/3/2011		$1.12	$1.12			View	N/A
11/2/2010	Q3 2010	$0.53	$0.53			View	N/A
8/3/2010	Q2 2010	$0.51	$0.52			View	N/A
5/3/2010	Q1 2010	$0.41	$0.41			View	N/A
2/5/2010	Q4 2009	$0.49	$0.50			View	N/A
11/2/2009	Q3 2009	$0.48	$0.52			View	N/A
8/4/2009	Q2 2009	$0.43	$0.47			View	N/A
5/7/2009	Q1 2009	$0.33	$0.37			View	N/A
2/5/2009	Q4 2008	$0.39	$0.41			View	N/A
11/5/2008	Q3 2008	$0.41	$0.41			View	N/A
8/5/2008	Q2 2008	$0.39	$0.40			View	N/A
5/8/2008	Q1 2008	$0.34	$0.33			View	N/A
2/6/2008	Q4 2007	$0.40	$0.40			View	N/A

(Earnings results data provided by Zacks Investment Research)

MEDNAX (NYSE:MD) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

MEDNAX (NYSE MD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.40%
Institutional Ownership Percentage: 98.53%

Insider Trading History for MEDNAX (NYSE:MD)

Institutional Ownership by Quarter for MEDNAX (NYSE:MD)

MEDNAX (NYSE MD) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/13/2018	John C Pepia	Insider	Sell	3,000	$58.35	$175,050.00	39,716
12/12/2017	John C Pepia	Insider	Sell	3,000	$51.58	$154,740.00	35,569
11/3/2017	Cesar L Alvarez	Director	Sell	10,668	$42.59	$454,350.12	44,215
9/12/2017	John C Pepia	Insider	Sell	3,000	$42.85	$128,550.00	35,569
6/14/2017	Md Pascal J Goldschmidt	Director	Sell	1,969	$57.57	$113,355.33	18,072
6/1/2017	Joseph M Calabro	Insider	Sell	23,327	$55.00	$1,282,985.00	296,379
5/5/2017	Manuel Kadre	Director	Buy	21,704	$55.79	$1,210,866.16	111,255
5/5/2017	Vivian Lopez-Blanco	CFO	Sell	7,778	$55.82	$434,167.96	51,319
3/16/2017	Robert Irwin Valliant	Director	Sell	5,200	$1.10	$5,720.00
2/23/2017	Enrique Sosa	Director	Sell	10,668	$69.65	$743,026.20	21,923
2/17/2017	Vivian Lopez-Blanco	CFO	Sell	15,164	$70.01	$1,061,631.64	59,097
2/16/2017	Dominic J Andreano	SVP	Sell	6,000	$69.59	$417,540.00	30,746
2/16/2017	John C Pepia	Insider	Sell	2,500	$69.58	$173,950.00	31,025
2/16/2017	Paul G Gabos	Director	Sell	21,336	$69.63	$1,485,625.68	21,923
2/10/2017	Md Pascal J Goldschmidt	Director	Sell	25,294	$67.82	$1,715,439.08	14,173
2/9/2017	Md Carlo A Waldemar	Director	Sell	5,334	$67.90	$362,178.60	16,589
1/17/2017	Vivian Lopez-Blanco	CFO	Sell	10,000	$70.95	$709,500.00	74,261
12/7/2016	Md Pascal J Goldschmidt	Director	Buy	2,100	$66.52	$139,692.00	13,355
9/14/2016	Md Pascal J Goldschmidt	Director	Sell	1,500	$65.01	$97,515.00	12,755
6/13/2016	Dominic J Andreano	SVP	Sell	3,922	$68.80	$269,833.60	24,746
6/8/2016	Md Carlo A Waldemar	Director	Sell	5,334	$70.50	$376,047.00	16,589
6/7/2016	Karl B Wagner	Insider	Sell	27,482	$68.45	$1,881,142.90	105,932
6/1/2016	Joseph M Calabro	COO	Sell	28,347	$67.78	$1,921,359.66	253,882
6/1/2016	Michael D Stanley	Insider	Sell	14,778	$67.78	$1,001,652.84	49,266
5/16/2016	Dominic J Andreano	SVP	Sell	3,000	$68.53	$205,590.00	21,313
5/2/2016	Vivian Lopez-Blanco	CFO	Sell	9,350	$71.22	$665,907.00	64,083
3/11/2016	Md Pascal J Goldschmidt	Director	Sell	3,100	$65.00	$201,500.00	12,479
2/29/2016	Paul G Gabos	Director	Sell	10,668	$67.15	$716,356.20	20,047
12/11/2015	Md Pascal J. Goldschmidt	Director	Sell	5,250	$70.99	$372,697.50	9,379
9/8/2015	Cesar L. Alvarez	Director	Sell	10,668	$81.00	$864,108.00	29,379
8/27/2015	Roger Md Medel	CEO	Sell	100,000	$80.27	$8,027,000.00	1,199,708
6/8/2015	Karl B Wagner	Insider	Sell	37,820	$70.28	$2,657,989.60
6/3/2015	Joseph M Calabro	COO	Sell	108,071	$70.51	$7,620,086.21
3/9/2015	Md Pascal J Goldschmidt	Director	Sell	8,500	$71.25	$605,625.00
2/26/2015	Roger Md Medel	CEO	Sell	100,000	$71.61	$7,161,000.00
2/20/2015	Md Carlo A Waldemar	Director	Sell	10,668	$71.50	$762,762.00
2/6/2015	Dominic J Andreano	SVP	Sell	3,200	$70.75	$226,400.00
2/6/2015	Vivian Lopez-Blanco	CFO	Sell	8,250	$69.95	$577,087.50
2/2/2015	Paul G Gabos	Director	Sell	17,584	$68.07	$1,196,942.88
1/30/2015	William C Hawk	COO	Sell	3,598	$68.50	$246,463.00
11/14/2014	Roger Md Medel	CEO	Sell	51,290	$62.59	$3,210,241.10
11/13/2014	Roger Md Medel	CEO	Sell	63,440	$62.55	$3,968,172.00
11/7/2014	Roger Md Medel	CEO	Sell	128,833	$62.60	$8,064,945.80
11/5/2014	Roger Md Medel	CEO	Sell	169,845	$62.60	$10,632,297.00
11/4/2014	Roger Md Medel	CEO	Sell	15,052	$62.52	$941,051.04
11/3/2014	Roger Md Medel	CEO	Sell	10,881	$62.52	$680,280.12
10/31/2014	Roger Md Medel	CEO	Sell	61,592	$62.58	$3,854,427.36
10/30/2014	Karl B Wagner	Insider	Sell	40,000	$62.50	$2,500,000.00
10/30/2014	Vivian Lopez-Blanco	CFO	Sell	8,800	$60.00	$528,000.00
7/30/2014	Karl B Wagner	Insider	Sell	80,000	$60.00	$4,800,000.00
6/10/2014	Dominic J Andreano	SVP	Sell	2,252	$58.48	$131,696.96
6/6/2014	Karl B Wagner	Insider	Sell	44,596	$58.53	$2,610,203.88
6/5/2014	William C Hawk	COO	Sell	6,911	$57.66	$398,488.26
6/2/2014	David A Clark	COO	Sell	16,230	$57.00	$925,110.00
6/2/2014	Michael D Stanley	Insider	Sell	18,006	$57.00	$1,026,342.00
5/9/2014	Karl Wagner	Insider	Sell	79,524	$57.09	$4,540,025.16	150,498
5/9/2014	Md Pascal Goldschmidt	Director	Sell	30,000	$57.11	$1,713,300.00	5,350
5/8/2014	Joseph Calabro	COO	Sell	137,500	$57.06	$7,845,750.00	226,542
2/20/2014	Dominic Andreano	SVP	Sell	3,000	$61.00	$183,000.00	16,135
2/10/2014	Joseph Calabro	COO	Sell	150,000	$55.55	$8,332,500.00	226,542
2/10/2014	Md Carlo Waldemar	Director	Sell	10,668	$55.40	$591,007.20	5,350
11/7/2013	Enrique Sosa	Director	Sell	5,334	$107.00	$570,738.00	2,675
11/7/2013	Karl Wagner	Insider	Sell	1,800	$107.60	$193,680.00	75,249
9/11/2013	William C Hawk	COO	Sell	3,162	$100.62	$318,160.44
9/10/2013	Dominic J Andreano	SVP	Sell	3,718	$99.63	$370,424.34
8/7/2013	Karl Wagner	Insider	Sell	25,000	$98.01	$2,450,250.00	75,249
8/2/2013	Joseph M Calabro	COO	Sell	36,154	$98.57	$3,563,699.78
6/3/2013	David A Clark	COO	Sell	8,645	$91.01	$786,781.45
6/3/2013	Michael D Stanley	Insider	Sell	8,906	$91.01	$810,535.06

(Data available from 1/1/2013 forward)

MEDNAX (NYSE MD) News Headlines

Source:

Date	Headline
	Comparing MEDNAX (MD) and Encompass Health (EHC) www.americanbankingnews.com - April 19 at 9:42 AM
	MedTech Stocks Q1 Earnings: Key Predictions for DGX, MD, CHE finance.yahoo.com - April 18 at 4:18 PM
	MEDNAX Inc (MD) Receives Average Rating of "Hold" from Analysts www.americanbankingnews.com - April 18 at 1:34 PM
	Head-To-Head Comparison: MEDNAX (MD) vs. Magellan Health (MGLN) www.americanbankingnews.com - April 18 at 3:20 AM
	$904.13 Million in Sales Expected for MEDNAX Inc (MD) This Quarter www.americanbankingnews.com - April 16 at 2:37 AM
	MEDNAX (MD) and Magellan Health (MGLN) Critical Survey www.americanbankingnews.com - April 15 at 11:15 AM
	MEDNAX (MD) Given a $46.00 Price Target at Jefferies Group www.americanbankingnews.com - April 15 at 9:45 AM
	Zacks: Brokerages Anticipate MEDNAX Inc (MD) Will Post Earnings of $0.85 Per Share www.americanbankingnews.com - April 14 at 5:09 PM
	Analyzing Encompass Health (EHC) & MEDNAX (MD) www.americanbankingnews.com - April 13 at 1:07 AM
	Edited Transcript of MD presentation 6-Mar-17 1:40pm GMT finance.yahoo.com - April 12 at 10:52 AM
	MEDNAX (MD) Rating Lowered to Sell at Zacks Investment Research www.americanbankingnews.com - April 11 at 8:58 AM
	MedData’s New Patient Financial Platform Solves Inefficient, Costly Revenue Cycle Challenges finance.yahoo.com - April 10 at 10:20 AM
	Financial Contrast: Encompass Health (EHC) & MEDNAX (MD) www.americanbankingnews.com - April 10 at 5:29 AM
	Analyzing MEDNAX (MD) and Magellan Health (MGLN) www.americanbankingnews.com - April 8 at 1:27 PM
	MEDNAX (MD) Rating Increased to Hold at Zacks Investment Research www.americanbankingnews.com - April 7 at 12:32 PM
	Southeast Anesthesiology: ‘Facts will speak’ in lawsuit against Atrium Health finance.yahoo.com - April 6 at 10:33 AM
	MEDNAX in Collaboration with Memorial Regional Hospital Earns National Accreditation for Adult Congenital Heart Program finance.yahoo.com - April 6 at 10:33 AM
	Head-To-Head Survey: MEDNAX (MD) and Magellan Health (MGLN) www.americanbankingnews.com - April 3 at 1:26 PM
	MEDNAX (MD) Lowered to "Sell" at ValuEngine www.americanbankingnews.com - April 3 at 12:11 PM
	Head to Head Comparison: Magellan Health (MGLN) & MEDNAX (MD) www.americanbankingnews.com - April 3 at 9:20 AM
	BRIEF-MEDNAX Announces Acquisition Of Pediatric Urology Practice In South Florida www.reuters.com - April 2 at 10:23 AM
	Mednax acquires medical practice with 3 South Florida offices www.bizjournals.com - April 2 at 10:23 AM
	MEDNAX (MD) Reports Acquisition of Pediatric Urology Practice in South Florida www.streetinsider.com - April 2 at 10:23 AM
	MEDNAX acquires Pediatric Urology practice in South Florida seekingalpha.com - April 2 at 10:23 AM
	MEDNAX Inc (MD) Expected to Post Quarterly Sales of $905.91 Million www.americanbankingnews.com - March 30 at 2:10 AM
	MEDNAX Sees Unusually Large Options Volume (MD) www.americanbankingnews.com - March 29 at 6:54 AM
	Critical Analysis: Tabula Rasa HealthCare (TRHC) versus MEDNAX (MD) www.americanbankingnews.com - March 28 at 5:40 PM
	Credit Suisse Takes Neutral Stance On Mednax, Says Buyout Value Reflected In Share Price www.msn.com - March 27 at 4:04 PM
	MEDNAX Announces Expansion of Radiology Practices finance.yahoo.com - March 27 at 10:22 AM
	MEDNAX (MD) Now Covered by Analysts at Credit Suisse Group www.americanbankingnews.com - March 27 at 8:45 AM
	MEDNAX (MD) PT Set at $50.00 by Jefferies Group www.americanbankingnews.com - March 25 at 12:14 PM
	MEDNAX Inc (MD) Receives Consensus Rating of "Hold" from Analysts www.americanbankingnews.com - March 24 at 1:50 PM
	BRIEF-Mednax Says CEO Roger Medel's Total Compensation For 2017 Was $7.4 Mln Versus $7.8 Mln In 2016 www.reuters.com - March 24 at 10:14 AM
	MEDNAX (MD) Cut to Hold at Zacks Investment Research www.americanbankingnews.com - March 21 at 8:54 PM
	BRIEF-Mednax Announces Acquisition Of Pediatric Ophthalmology Practice In Washington www.reuters.com - March 21 at 4:00 PM
	MEDNAX Announces Acquisition of Pediatric Ophthalmology Practice in Washington finance.yahoo.com - March 21 at 11:09 AM
	Should Value Investors Pick MEDNAX (MD) Stock? finance.yahoo.com - March 21 at 11:09 AM
	MEDNAX (MD) Given a $58.00 Price Target at Jefferies Group www.americanbankingnews.com - March 17 at 4:28 PM
	[$$] Medical Wars finance.yahoo.com - March 17 at 10:10 AM
	John C. Pepia Sells 3,000 Shares of MEDNAX Inc (MD) Stock www.americanbankingnews.com - March 14 at 7:49 PM
	MEDNAX (MD) Upgraded by TheStreet to "B" www.americanbankingnews.com - March 14 at 7:20 AM
	Brokerages Anticipate MEDNAX Inc (MD) Will Post Earnings of $0.84 Per Share www.americanbankingnews.com - March 11 at 1:18 PM
	What Analysts Recommend for American Renal Associates Holdings finance.yahoo.com - March 9 at 4:57 PM
	Veeva Systems Rides on Strong Q4 & Cloud-Based Applications finance.yahoo.com - March 8 at 10:23 AM
	Cerner-Centrus Health to Collaborate, HealtheIntent in Focus finance.yahoo.com - March 7 at 4:50 PM
	The Manufacturers Life Insurance Company Acquires 17,163 Shares of MEDNAX Inc (MD) www.americanbankingnews.com - March 6 at 3:12 PM
	Cerner Collaborates With Salesforce, Focuses on AI Trends www.msn.com - March 6 at 9:51 AM
	Bank of New York Mellon Corp Sells 31,948 Shares of MEDNAX Inc (MD) www.americanbankingnews.com - March 6 at 4:54 AM
	MEDNAX Inc (MD) Shares Sold by Green Valley Investors LLC www.americanbankingnews.com - March 5 at 2:54 PM
	Kindred Healthcare (KND) and MEDNAX (MD) Critical Analysis www.americanbankingnews.com - March 5 at 1:18 PM

MEDNAX (NYSE:MD) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

MEDNAX (NYSE:MD) Income Statement, Balance Sheet and Cash Flow Statement

MEDNAX (NYSE MD) Stock Chart for Thursday, April, 19, 2018

Loading chart…

This page was last updated on 4/19/2018 by MarketBeat.com Staff